Trial Profile
A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of GBT440 on the Pharmacokinetics of Probe Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary) ; Midazolam; Omeprazole
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Global Blood Therapeutics
- 10 Apr 2017 Status changed from recruiting to completed.
- 09 Oct 2015 New trial record